These molecules are expressed on activated T cells, but when they adhere to ligands either on APC (CTLA-4 binding to CD80/CD86) or tumor cells (PD-1 binding to PD-L1), they tend to suppress the antitumor response. Here, CTLA4 is linked to neoplasm.